Immunobiome Wins Grand Prize for Academic Achievement at the 2020 Korean Association of Immunologists International Conference for Contributions to Immunology Advancement

[Asia Economy Reporter Hyunseok Yoo] Immunobiome, a microbiome therapeutic research and development company, announced on the 13th that it won the Grand Prize for Academic Achievement at the ‘2020 Korean Association of Immunologists (KAI) International Meeting’ held from the 11th.

The Korean Association of Immunologists, established in 1974, is the leading academic society in the field of immunology in Korea, with over 1,200 members. It holds an annual autumn international regular academic conference to exchange research achievements and the latest research information in immunology domestically and internationally, and selects researchers who have made significant contributions to the academic development of immunology.

Shinhyuk Lim, CEO of Immunobiome and professor in the Department of Life Sciences at POSTECH, received this year’s Grand Prize for Academic Achievement in recognition of his contributions to the advancement of immunology.

CEO Lim has conducted research over the past 20 years on immunological genetic factors and gut bacteria that play important roles in disease occurrence and health maintenance. In particular, he has made significant contributions to the ‘microbial new drug development’ research by identifying immune-regulating or immune-enhancing bacteria (probiotics) that can correct abnormal immune responses in disease states using gut bacteria, and by elucidating active substances and mechanisms of action to utilize microbes themselves as drugs.

Shinhyuk Lim, CEO of Immunobiome, said, “It is an honor and a great sense of mission to receive the Grand Prize for Academic Achievement during the COVID-19 period, when immunologists face numerous challenges. I will devote myself further to research so that basic immunology research results on microbial new drug development can lead to the development of intractable disease treatments that directly benefit patients.”

He added, “The microbiome-based microbiome therapeutic field is a blue ocean new growth business sector showing very steep growth, with a global market size predicted to reach 100 billion dollars (approximately 111 trillion won) by 2023. We will focus more on developing microbial new drugs that can treat intractable diseases such as autism, cancer, and lupus, and accelerate the development of clinically applicable therapeutics through close cooperation with clinical researchers.”

This content was produced with the assistance of AI translation services.